Anne I. Dipchand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne I. Dipchand has a total of 587 co-authors. Here are the top co-authors by number of shared publications:
Cedric Manlhiot
Labatt Family Heart Centre, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
10 shared publicationsRichard Kirk
Division of Pediatric Cardiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
9 shared publications- Ryan Robert Davies
UT Southwestern Med Ctr, Dept Cardiovasc & Thorac Surg, 1935 Med Dist Dr,MC B3-410, Dallas, TX 75235 USA
9 shared publications Brian W. McCrindle
Labatt Family Heart Centre, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
8 shared publicationsOliver Miera
Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum, Berlin, Germany
7 shared publications- Upton Allen
Division of Infectious Diseases and the Transplant and Regenerative Medicine Center, Department of Paediatrics, Hospital for Sick Children University of Toronto Toronto Ontario Canada
7 shared publications
Latest Publications
- 16 October 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-11
Transplantation for Congenital Heart Disease in Children—A Quest to Do Better
Children with congenital heart disease (CHD) represent the largest group of pediatric heart transplant recipients but experience lower graft survival than those transplanted for cardiomyopathy. We evaluated post-transplant outcomes among CHD recipients at the Hospital for Sick Children (HSC) and identified predictors of graft loss. Pediatric patients (< 17 years) undergoing heart transplantation for CHD between 1993 and 2023 were analyzed using the Pediatric Heart Transplant Society registry. Outcomes of CHD recipients at HSC (CHD HSC) were compared with cardiomyopathy HSC recipients, CHD recipients at other centers (CHD Non-HSC), and a propensity score-matched (PSM) cohort adjusting for pre- and peri-transplant risk factors. Kaplan-Meier survival and multivariable Cox proportional hazards analyses were performed. Among 4,362 pediatric CHD transplant recipients, 152 underwent transplantation at HSC. Freedom from graft loss for CHD HSC at 5, 10, and 15 years was 71.8%, 63.0%, and 58.4%, lower than in Cardiomyopathy HSC recipients (p < 0.0001), but similar to CHD Non-HSC (p = 0.6043). Survival remained comparable in the PSM cohort (n = 140, p = 0.4599). Conditional survival beyond 1 year was similar between groups, suggesting early mortality drives differences. CHD HSC recipients demonstrated longer freedom from CAV (p = 0.0041) and infection (p = 0.0335). Predictors of graft loss included pre-transplant ECMO (HR 3.11), ICU admission (HR 2.39), PRA > 10% (HR 2.49), African American/Black race/ethnicity (HR 2.71), and longer waitlist duration (HR 1.06). Graft survival in CHD recipients at HSC remains lower than in cardiomyopathy recipients but comparable internationally. Optimizing pre-transplant care, sensitization management, and equity-focused interventions may enhance outcomes.
- 16 October 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-11
Transplantation for Congenital Heart Disease in Children—A Quest to Do Better
Children with congenital heart disease (CHD) represent the largest group of pediatric heart transplant recipients but experience lower graft survival than those transplanted for cardiomyopathy. We evaluated post-transplant outcomes among CHD recipients at the Hospital for Sick Children (HSC) and identified predictors of graft loss. Pediatric patients (< 17 years) undergoing heart transplantation for CHD between 1993 and 2023 were analyzed using the Pediatric Heart Transplant Society registry. Outcomes of CHD recipients at HSC (CHD HSC) were compared with cardiomyopathy HSC recipients, CHD recipients at other centers (CHD Non-HSC), and a propensity score-matched (PSM) cohort adjusting for pre- and peri-transplant risk factors. Kaplan-Meier survival and multivariable Cox proportional hazards analyses were performed. Among 4,362 pediatric CHD transplant recipients, 152 underwent transplantation at HSC. Freedom from graft loss for CHD HSC at 5, 10, and 15 years was 71.8%, 63.0%, and 58.4%, lower than in Cardiomyopathy HSC recipients (p < 0.0001), but similar to CHD Non-HSC (p = 0.6043). Survival remained comparable in the PSM cohort (n = 140, p = 0.4599). Conditional survival beyond 1 year was similar between groups, suggesting early mortality drives differences. CHD HSC recipients demonstrated longer freedom from CAV (p = 0.0041) and infection (p = 0.0335). Predictors of graft loss included pre-transplant ECMO (HR 3.11), ICU admission (HR 2.39), PRA > 10% (HR 2.49), African American/Black race/ethnicity (HR 2.71), and longer waitlist duration (HR 1.06). Graft survival in CHD recipients at HSC remains lower than in cardiomyopathy recipients but comparable internationally. Optimizing pre-transplant care, sensitization management, and equity-focused interventions may enhance outcomes.
- 23 May 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (5) , e70343
Ionizing Radiation Exposure From Imaging in Pediatric Solid Organ Transplant Recipients
Background: Pediatric solid organ transplant recipients undergo extensive medical imaging. Limited data are available on the cumulative radiation dose from imaging. Our aim was to quantify cumulative ionizing radiation exposure and define its contributors. Methods: Retrospective cohort study of children (0–18 years) who received their first solid organ transplant (heart, lung, liver, kidney, or multi‐organ) at a tertiary care children's hospital in Toronto, Canada over a 10‐year period. Participants were followed from their first imaging procedure pre‐transplantation until transfer of care, death, or 28‐months after enrollment. The primary outcome was cumulative effective dose (CED; in millisieverts [mSv]) of ionizing radiation. CED estimates were stratified by era (pre‐ and post‐transplant), imaging modality, imaging indication, and transplant organ group. Results: Among 543 pediatric solid organ transplant recipients, 29 821 imaging studies were conducted over median 3.4‐year (IQR 1.0–6.1) follow‐up. Median estimated CED was 21 mSv (IQR 9–41) and median 39 (IQR 20–71) imaging studies were performed per child. Throughout follow‐up, 259 (48%) children were exposed to a CED ≤ 20 mSv, 168 (31%) to 20–50 mSv, 71 (13%) to 50–100 mSv, and 45 (8%) to > 100 mSv. Computed tomography was the highest contributor to CED (44%), with most studies performed for clinical care. Only 20% of CED was attributable to planned per‐protocol imaging. Radiation exposure was highest in multi‐organ transplant recipients and lowest in kidney recipients. Conclusions: Radiation exposure from medical imaging was low‐to‐moderate for most pediatric solid organ transplant recipients. Emphasis on optimizing ionizing modalities to reduce radiation dose and the promotion of non‐ionizing imaging modalities remains important.
- 23 May 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (5) , e70343
Ionizing Radiation Exposure From Imaging in Pediatric Solid Organ Transplant Recipients
Background: Pediatric solid organ transplant recipients undergo extensive medical imaging. Limited data are available on the cumulative radiation dose from imaging. Our aim was to quantify cumulative ionizing radiation exposure and define its contributors. Methods: Retrospective cohort study of children (0–18 years) who received their first solid organ transplant (heart, lung, liver, kidney, or multi‐organ) at a tertiary care children's hospital in Toronto, Canada over a 10‐year period. Participants were followed from their first imaging procedure pre‐transplantation until transfer of care, death, or 28‐months after enrollment. The primary outcome was cumulative effective dose (CED; in millisieverts [mSv]) of ionizing radiation. CED estimates were stratified by era (pre‐ and post‐transplant), imaging modality, imaging indication, and transplant organ group. Results: Among 543 pediatric solid organ transplant recipients, 29 821 imaging studies were conducted over median 3.4‐year (IQR 1.0–6.1) follow‐up. Median estimated CED was 21 mSv (IQR 9–41) and median 39 (IQR 20–71) imaging studies were performed per child. Throughout follow‐up, 259 (48%) children were exposed to a CED ≤ 20 mSv, 168 (31%) to 20–50 mSv, 71 (13%) to 50–100 mSv, and 45 (8%) to > 100 mSv. Computed tomography was the highest contributor to CED (44%), with most studies performed for clinical care. Only 20% of CED was attributable to planned per‐protocol imaging. Radiation exposure was highest in multi‐organ transplant recipients and lowest in kidney recipients. Conclusions: Radiation exposure from medical imaging was low‐to‐moderate for most pediatric solid organ transplant recipients. Emphasis on optimizing ionizing modalities to reduce radiation dose and the promotion of non‐ionizing imaging modalities remains important.
- 19 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1095-1102
Safety and immunogenicity of varicella-zoster vaccination in pediatric heart transplant recipients
- 19 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1095-1102
Safety and immunogenicity of varicella-zoster vaccination in pediatric heart transplant recipients
- 4 March 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-12
Early Experience with the First Canadian Paediatric Fontan Long-Term Follow-up Clinic
The Fontan procedure has significantly improved survival in patients with single-ventricle physiology; however, multisystem complications have become a major source of late morbidity and mortality. In 2020, the Hospital for Sick Children (SickKids) established a dedicated paediatric Fontan Long-Term Follow-up Clinic. This study evaluated the prevalence and spectrum of cardiac and extracardiac morbidities in the clinic cohort since inception. This single-centre retrospective study included all patients referred between January 2020 and December 2024. Standardized assessments comprised cardiac evaluations (echocardiography, Holter monitoring, exercise testing, cardiac MRI) and extracardiac investigations of hepatic, renal, hematologic, endocrine, growth, and neurodevelopmental status. Fontan-associated liver disease (FALD) was graded using MR elastography and imaging findings. A total of 161 patients (mean age 13.2 ± 3.7 years; 58.4% male) were assessed at a mean of 9.5 ± 4.3 years post-Fontan completion. Tricuspid atresia was the most common diagnosis (26.1%). Cardiac function was generally preserved, with mean predicted peak VO₂ of 63.6 ± 17.6%. Moderate or severe atrioventricular valve regurgitation occurred in 21.5%, and ventricular dysfunction in 5.6%. Moderate or greater FALD was observed in 8.0%, with mean magnetic resonance elastography 4.58 kPa (Interquartile range, 4.03–5.40). Lymphopenia (64.6%), thrombocytopenia (16.8%), vitamin D deficiency (41.9%), and reduced bone density (28.0%) were frequent. Neurodevelopmental challenges were common (39.8% learning difficulties). Despite preserved cardiac performance, Fontan patients exhibited a high burden of hepatic, hematologic, endocrine, skeletal, and neurocognitive morbidities. Multidisciplinary, longitudinal follow-up is essential to optimize outcomes and quality of life.
- 4 March 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-12
Early Experience with the First Canadian Paediatric Fontan Long-Term Follow-up Clinic
The Fontan procedure has significantly improved survival in patients with single-ventricle physiology; however, multisystem complications have become a major source of late morbidity and mortality. In 2020, the Hospital for Sick Children (SickKids) established a dedicated paediatric Fontan Long-Term Follow-up Clinic. This study evaluated the prevalence and spectrum of cardiac and extracardiac morbidities in the clinic cohort since inception. This single-centre retrospective study included all patients referred between January 2020 and December 2024. Standardized assessments comprised cardiac evaluations (echocardiography, Holter monitoring, exercise testing, cardiac MRI) and extracardiac investigations of hepatic, renal, hematologic, endocrine, growth, and neurodevelopmental status. Fontan-associated liver disease (FALD) was graded using MR elastography and imaging findings. A total of 161 patients (mean age 13.2 ± 3.7 years; 58.4% male) were assessed at a mean of 9.5 ± 4.3 years post-Fontan completion. Tricuspid atresia was the most common diagnosis (26.1%). Cardiac function was generally preserved, with mean predicted peak VO₂ of 63.6 ± 17.6%. Moderate or severe atrioventricular valve regurgitation occurred in 21.5%, and ventricular dysfunction in 5.6%. Moderate or greater FALD was observed in 8.0%, with mean magnetic resonance elastography 4.58 kPa (Interquartile range, 4.03–5.40). Lymphopenia (64.6%), thrombocytopenia (16.8%), vitamin D deficiency (41.9%), and reduced bone density (28.0%) were frequent. Neurodevelopmental challenges were common (39.8% learning difficulties). Despite preserved cardiac performance, Fontan patients exhibited a high burden of hepatic, hematologic, endocrine, skeletal, and neurocognitive morbidities. Multidisciplinary, longitudinal follow-up is essential to optimize outcomes and quality of life.
- Open Access
- 18 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (1)
From sudden stroke to heart transplant: unmasking restrictive cardiomyopathy in an adolescent: a case report
Background: Paediatric acute ischaemic stroke (AIS) is a challenging diagnostic entity. A comprehensive cardiac evaluation is essential in all paediatric AIS cases to rule out cardioembolic sources. We present the case of a teenage female with AIS who was found to have restrictive cardiomyopathy (RCM). Case summary: A 15-year-old female presented to the emergency department with left-sided paresis, hemi-neglect, and facial paralysis. Neuroimaging demonstrated a right middle cerebral artery infarct and mechanical thrombectomy was performed. Chest radiography revealed cardiomegaly and pulmonary oedema, and electrocardiogram (ECG) showed biatrial enlargement with repolarization abnormalities. Echocardiography revealed RCM, which was subsequently confirmed by cardiac magnetic resonance imaging, providing support for a cardioembolic source, and she received a heart transplant. Genetic testing ultimately identified a heterozygous pathogenic variant in MYH7. Discussion: Paediatric AIS is uncommon and frequently idiopathic, with cardioembolism accounting for ∼15% of adolescent cases. Restrictive cardiomyopathy, although rare, should be considered in the differential, as thromboembolic complications occur in up to one-third of patients, with nearly half of these involving the cerebral circulation. Importantly, stroke may be the first manifestation of the disease. Early cardiac screening, including ECG, chest radiography, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and echocardiography, is crucial in the early diagnostic work-up of paediatric AIS. Prompt recognition of diastolic dysfunction and atrial enlargement may accelerate diagnosis and inform timely referral for heart transplantation. In short, paediatric AIS, though rare, requires thorough diagnostic evaluation to identify potential cardioembolic sources.
- 18 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (1)
Open AccessFrom sudden stroke to heart transplant: unmasking restrictive cardiomyopathy in an adolescent: a case report
Background: Paediatric acute ischaemic stroke (AIS) is a challenging diagnostic entity. A comprehensive cardiac evaluation is essential in all paediatric AIS cases to rule out cardioembolic sources. We present the case of a teenage female with AIS who was found to have restrictive cardiomyopathy (RCM). Case summary: A 15-year-old female presented to the emergency department with left-sided paresis, hemi-neglect, and facial paralysis. Neuroimaging demonstrated a right middle cerebral artery infarct and mechanical thrombectomy was performed. Chest radiography revealed cardiomegaly and pulmonary oedema, and electrocardiogram (ECG) showed biatrial enlargement with repolarization abnormalities. Echocardiography revealed RCM, which was subsequently confirmed by cardiac magnetic resonance imaging, providing support for a cardioembolic source, and she received a heart transplant. Genetic testing ultimately identified a heterozygous pathogenic variant in MYH7. Discussion: Paediatric AIS is uncommon and frequently idiopathic, with cardioembolism accounting for ∼15% of adolescent cases. Restrictive cardiomyopathy, although rare, should be considered in the differential, as thromboembolic complications occur in up to one-third of patients, with nearly half of these involving the cerebral circulation. Importantly, stroke may be the first manifestation of the disease. Early cardiac screening, including ECG, chest radiography, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and echocardiography, is crucial in the early diagnostic work-up of paediatric AIS. Prompt recognition of diastolic dysfunction and atrial enlargement may accelerate diagnosis and inform timely referral for heart transplantation. In short, paediatric AIS, though rare, requires thorough diagnostic evaluation to identify potential cardioembolic sources.
- 6 November 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70223
A Decade of Pediatric Ventricular Assist Device Support in Colombia, a Middle‐Income Country
Background: Heart transplantation is the main treatment for refractory end‐stage heart failure in patients of all ages, but its use is limited by the availability of organs, especially in pediatric populations. The International Hospital of Colombia has been a pioneer and the single center with the capability in the country for providing ventricular assist device (VAD) support using the CentriMag/PediMag‐Levitronix paracorporeal VAD for pediatric patients awaiting transplant, with over a decade of experience albeit with many challenges. Methods: This retrospective study examines outcomes from 26 pediatric patients who received VAD support between 2012 and 2023. Results: Most patients were diagnosed with dilated cardiomyopathy ( n = 20, 77%), had an average age of 8.5 years (SD 5.3), and ranged in weight from 5 to 59 kg. The median duration of VAD support was 50.5 days, with 17 (81%) of surviving patients ( n = 21), successfully undergoing transplantation. Neurological injury was the most common complication, affecting 69% of patients. The overall survival rate to VAD support was 81% and patients with left ventricular assist devices (LVAD) showed a higher post‐transplant survival rate compared to those with biventricular assist devices (BiVAD). Conclusions: This comparative analysis highlights the challenges faced in Colombia, particularly in implementing advanced medical technologies in middle‐income countries. Despite these constraints, the study demonstrates notable patient survival, suggesting that targeted efforts to improve resource allocation and technology access could further enhance results.
- 6 November 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70223
A Decade of Pediatric Ventricular Assist Device Support in Colombia, a Middle‐Income Country
Background: Heart transplantation is the main treatment for refractory end‐stage heart failure in patients of all ages, but its use is limited by the availability of organs, especially in pediatric populations. The International Hospital of Colombia has been a pioneer and the single center with the capability in the country for providing ventricular assist device (VAD) support using the CentriMag/PediMag‐Levitronix paracorporeal VAD for pediatric patients awaiting transplant, with over a decade of experience albeit with many challenges. Methods: This retrospective study examines outcomes from 26 pediatric patients who received VAD support between 2012 and 2023. Results: Most patients were diagnosed with dilated cardiomyopathy ( n = 20, 77%), had an average age of 8.5 years (SD 5.3), and ranged in weight from 5 to 59 kg. The median duration of VAD support was 50.5 days, with 17 (81%) of surviving patients ( n = 21), successfully undergoing transplantation. Neurological injury was the most common complication, affecting 69% of patients. The overall survival rate to VAD support was 81% and patients with left ventricular assist devices (LVAD) showed a higher post‐transplant survival rate compared to those with biventricular assist devices (BiVAD). Conclusions: This comparative analysis highlights the challenges faced in Colombia, particularly in implementing advanced medical technologies in middle‐income countries. Despite these constraints, the study demonstrates notable patient survival, suggesting that targeted efforts to improve resource allocation and technology access could further enhance results.
- 25 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1195-1198
The Authors’ Perspective on 'Summary of the International Society for Heart and Lung Transplantation Consensus Conference on Emerging Understanding of Antibodies and Antibody-mediated Rejection in Heart Transplantation'
- 25 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (8) , 1195-1198
The Authors’ Perspective on 'Summary of the International Society for Heart and Lung Transplantation Consensus Conference on Emerging Understanding of Antibodies and Antibody-mediated Rejection in Heart Transplantation'
- 15 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1953-1954
Response to Shen and Li
- 15 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1953-1954
Response to Shen and Li
- 24 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1809-1816
Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study
Background: Cancer treatment can lead to organ toxicity requiring solid organ transplant. Transplant teams must evaluate the appropriateness of solid organ transplant in survivors of childhood or adolescent and young adult cancer. Methods: Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986 and 2021 and adolescent and young adult (aged 15-21 years) treated in an adult center for 5 common cancer types between 1992 and 2012 were identified using population-based databases. Outcomes were determined by linkage to administrative databases. Transplanted cancer survivors were matched 1:2 to solid organ transplant recipients without a prior cancer. Post–solid organ transplant overall survival, subsequent cancers, severe cardiovascular disease, and graft loss or death were compared between groups. Results: Among 16 533 cancer survivors, 52 received a solid organ transplant: 13 liver, 18 kidney, 11 lung, and 10 heart. Median age at solid organ transplant was 18 years (interquartile range [IQR] = 14-27 years). Transplanted cancer survivors experienced lower 10-year post–solid organ transplant overall survival than transplanted individuals with a history of cancer (67.7 vs 86.0%; P = .003). Ten-year cumulative incidence of developing another de novo malignancy was 8.6%, similar to the incidence of first cancers among individuals without a prior cancer history (12.9%; hazard ratio [HR] = 1.05, P = .91). Ten-year cumulative incidence of primary cancer recurrence was 10.5%. Transplanted cancer survivors (excluding heart transplants) were at risk for graft loss or death (HR = 2.00, 95% confidence interval [CI] = 1.01 to 3.94) but not severe cardiovascular disease (HR = 1.10, 95% CI = 0.50 to 2.41). Conclusion: Survivors treated with solid organ transplant had inferior survival than solid organ transplant recipients without a cancer history, but most achieved long-term cancer-free survival. These data can inform decisions around the suitability of cancer survivors for solid organ transplant.
- 24 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1809-1816
Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study
Background: Cancer treatment can lead to organ toxicity requiring solid organ transplant. Transplant teams must evaluate the appropriateness of solid organ transplant in survivors of childhood or adolescent and young adult cancer. Methods: Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986 and 2021 and adolescent and young adult (aged 15-21 years) treated in an adult center for 5 common cancer types between 1992 and 2012 were identified using population-based databases. Outcomes were determined by linkage to administrative databases. Transplanted cancer survivors were matched 1:2 to solid organ transplant recipients without a prior cancer. Post–solid organ transplant overall survival, subsequent cancers, severe cardiovascular disease, and graft loss or death were compared between groups. Results: Among 16 533 cancer survivors, 52 received a solid organ transplant: 13 liver, 18 kidney, 11 lung, and 10 heart. Median age at solid organ transplant was 18 years (interquartile range [IQR] = 14-27 years). Transplanted cancer survivors experienced lower 10-year post–solid organ transplant overall survival than transplanted individuals with a history of cancer (67.7 vs 86.0%; P = .003). Ten-year cumulative incidence of developing another de novo malignancy was 8.6%, similar to the incidence of first cancers among individuals without a prior cancer history (12.9%; hazard ratio [HR] = 1.05, P = .91). Ten-year cumulative incidence of primary cancer recurrence was 10.5%. Transplanted cancer survivors (excluding heart transplants) were at risk for graft loss or death (HR = 2.00, 95% confidence interval [CI] = 1.01 to 3.94) but not severe cardiovascular disease (HR = 1.10, 95% CI = 0.50 to 2.41). Conclusion: Survivors treated with solid organ transplant had inferior survival than solid organ transplant recipients without a cancer history, but most achieved long-term cancer-free survival. These data can inform decisions around the suitability of cancer survivors for solid organ transplant.